Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMADA: DLL3-SAVVYZ-IL18 CAR T Cells in R/R Metastatic DLL3+ Cancers
NCT07783477Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of DLL3-SAVVYZ-IL18 CAR T cell in neuroendocrine cancer and small cell lung cancer (SCLC) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Aug 2026; status: recruiting.
02
Drugs
DLL3-SAVVYZ-IL18 CAR T cell
03
Conditions
neuroendocrine cancersmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07783477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783477.